Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Colorcon
Dow
Boehringer Ingelheim

Last Updated: January 27, 2023

Investigational Drug Information for BGB-3111


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for BGB-3111?

BGB-3111 is an investigational drug.

There have been 123 clinical trials for BGB-3111. The most recent clinical trial was a Phase 2 trial, which was initiated on January 25th 2017.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are BeiGene, National Cancer Institute (NCI), and BeiGene USA, Inc.

There are nine US patents protecting this investigational drug and eighty-three international patents.

Recent Clinical Trials for BGB-3111
TitleSponsorPhase
Mirdametinib + BGB-3245 in Advanced Solid TumorsSpringWorks Therapeutics, Inc.Phase 1/Phase 2
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsBeiGenePhase 1
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.BeiGenePhase 1/Phase 2

See all BGB-3111 clinical trials

Clinical Trial Summary for BGB-3111

Top disease conditions for BGB-3111
Top clinical trial sponsors for BGB-3111

See all BGB-3111 clinical trials

US Patents for BGB-3111

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-3111 See Plans and Pricing Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (Grand Cayman, KY) See Plans and Pricing
BGB-3111 See Plans and Pricing Treatment of pemphigus PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) See Plans and Pricing
BGB-3111 See Plans and Pricing Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BEIGENE SWITZERLAND GMBH (Basel, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Colorcon
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.